Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Idexx Laboratories (IDXX)
NASDAQ:IDXX
Holding IDXX?
Track your performance easily
IDXX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$404.74 - $583.39
Previous Close$416.34
Volume502.18K
Average Volume (3M)532.13K
Market Cap
$34.18B
Enterprise Value$34.76B
Total Cash (Recent Filing)$308.64M
Total Debt (Recent Filing)$977.32M
Price to Earnings (P/E)40.2
Beta1.48
Next Earnings
Feb 10, 2025EPS Estimate
$2.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.36
Shares Outstanding81,884,664
10 Day Avg. Volume708,348
30 Day Avg. Volume532,135
Standard Deviation0.10
R-Squared0.47
Alpha-0.00491
Financial Highlights & Ratios
Price to Book (P/B)21.07
Price to Sales (P/S)8.96
Price to Cash Flow (P/CF)39.10
P/FCF Ratio44.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.04
Enterprise Value/Gross Profit15.87
Enterprise Value/Ebitda36.30
Forecast
1Y Price Target
$491.43Price Target Upside17.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Idexx Laboratories News
PremiumCompany Announcements
Idexx Laboratories Announces CEO Jonathan Ayers’ Resignation
PremiumCompany Announcements
IDEXX Laboratories Reports Robust Q3 2024 Performance
Bulls Say, Bears Say
Bulls Say
Financial Performance And InnovationThe largely maintained normalized EPS and margin target, despite lower revenue, demonstrates IDXX's ability to manage costs effectively.
Growth Opportunities In OncologyIDXX Cancer Dx is seen as a key growth driver with a $1 billion addressable revenue opportunity.
Product Launch And Market InterestEarly customer enthusiasm for InVue Dx is high, with a significant number of pre-orders and plans to expand its testing menu.
Bears Say
Consumer SpendingConsumers are starting to moderate their vet spending after aggressive price taking across the industry, limiting IDEXX’s ability to use price as a lever going forward.
Revenue GrowthThe updated guidance implies organic growth of only 2.9% in the fourth quarter, driven by 3.6% organic CAG recurring growth, which is the lowest trend since early 2013.
Veterinary Clinic VisitsPersistent weakness in veterinary clinic visit trends and a challenging macro backdrop drove repeated cuts to IDXX's FY24 outlook this year.
---
Ownership Overview
0.97% Insiders
27.33% Mutual Funds
19.67% Other Institutional Investors
22.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IDXX FAQ
What was Idexx Laboratories’s price range in the past 12 months?
Idexx Laboratories lowest stock price was $404.74 and its highest was $583.39 in the past 12 months.
What is Idexx Laboratories’s market cap?
Currently, no data Available
When is Idexx Laboratories’s upcoming earnings report date?
Idexx Laboratories’s upcoming earnings report date is Feb 10, 2025 which is in 81 days.
How were Idexx Laboratories’s earnings last quarter?
Idexx Laboratories released its earnings results on Oct 31, 2024. The company reported $2.8 earnings per share for the quarter, beating the consensus estimate of $2.681 by $0.119.
Is Idexx Laboratories overvalued?
According to Wall Street analysts Idexx Laboratories’s price is currently Undervalued.
Does Idexx Laboratories pay dividends?
Idexx Laboratories does not currently pay dividends.
What is Idexx Laboratories’s EPS estimate?
Idexx Laboratories’s EPS estimate is $2.39.
How many shares outstanding does Idexx Laboratories have?
Idexx Laboratories has 81,884,670 shares outstanding.
What happened to Idexx Laboratories’s price movement after its last earnings report?
Idexx Laboratories reported an EPS of $2.8 in its last earnings report, beating expectations of $2.681. Following the earnings report the stock price went down -9.79%.
Which hedge fund is a major shareholder of Idexx Laboratories?
Among the largest hedge funds holding Idexx Laboratories’s share is Spence Asset Management. It holds Idexx Laboratories’s shares valued at 22M.
---
Idexx Laboratories Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$491.43 (17.72% Upside)
$491.43 (17.72% Upside)
Blogger Sentiment
Bullish
IDXX Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $234.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.21%
12-Months-Change
Fundamentals
Return on Equity
59.42%
Trailing 12-Months
Asset Growth
8.57%
Trailing 12-Months
Company Description
Idexx Laboratories
Maine-based IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
---
IDXX Company Deck
---
IDXX Earnings Call
Q3 2024
0:00 / 0:00
---
IDXX Revenue Breakdown
34.93% Reference laboratory diagnostic and consulting services
32.46% IDEXX VetLab consumables
9.41% Rapid assay products
7.63% Veterinary software, services and diagnostic imaging systems
15.58% Other
---
IDXX Stock 12 Month Forecast
Average Price Target
$491.43
▲(17.72% Upside)
Technical Analysis
Best Analysts Covering IDXX
1 Year
1 Year Success Rate
12/20 ratings generated profit
1 Year Average Return
+14.66%
reiterated a buy rating 21 days ago
Copying Erin Wright's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +14.66% per trade.
---